John Armitage
Egerton Capital
John Armitage Boston Scientific Corp stake
total: 222
Egerton Capital BSX trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Held since:
- 2025 Q2
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, John Armitage doesn't hold any Boston Scientific Corp (BSX) shares. To date, the estimated cost basis is nearly $100.58 for "buy" trades and estimated average "sell" price is $95.35. Egerton Capital first purchased BSX in 2025 Q2, initially acquiring about 1.64M shares. Since the initial investment in Boston Scientific Corp (BSX), Egerton Capital has made 3 more transactions.
When did John Armitage sell Boston Scientific Corp (BSX)?
John Armitage sold off the entire Boston Scientific Corp (BSX) position in 2026 Q1.
When did John Armitage buy Boston Scientific Corp (BSX)?
John Armitage first invested in Boston Scientific Corp (BSX) in 2025 Q2 at the reported quarter-end price of $107.41 per share.
What's the cost basis of Egerton Capital's BSX stake?
The estimated cost basis for Boston Scientific Corp (BSX) stake is around $100.58 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $100.58
- Weighted AVG sell price:
- $95.35
John Armitage's historical trades in Boston Scientific Corp
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$95.35
|
|
-100% (-5,385,084)
|
-5.58%
|
|
2025 Q4
|
5.58%
|
5,385,084
|
$95.35
|
$513,467,759
|
+1.37% (+72,580)
|
+0.08%
|
|
2025 Q3
|
5.47%
|
5,312,504
|
$97.63
|
$518,659,766
|
+223.74% (+3,671,548)
|
+3.78%
|
|
2025 Q2
|
1.81%
|
1,640,956
|
$107.41
|
$176,255,084
|
new
|
+1.81%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.